Novartis Report Results of Kesimpta (ofatumumab) Sensoready Autoinjector Pen for Multiple Sclerosis

Novartis Report Outcomes of Kesimpta (ofatumumab) Sensoready autoinjector pen for Numerous Sclerosis

Shots:

The multicenter survey involves evaluating Kesimpta Sensoready autoinjector pen in 80 MS patients and 50 MS nurses, with RMS who got an illness modifying treatment through a subcutaneous/intramuscular injection via an autoinjector
The outcome shows MS clients and nurses choose the Kesimpta Sensoready autoinjector pen over other autoinjectors for current treatment (84% vs 16%). The findings will be provided at the ACTRIMS Forum 2021 on Feb, 2021
Kesimpta received positive CHMP viewpoint last month based on two P-III trials showed decrease of yearly relapses by over 50% with more than 30% relative threat reduction of 3 mos. CDP vs teriflunomide

Click here to check out complete news release/ post|Ref: Novartis|Image: PMLiVE

Post Views:
17